Seattle, WA -- (SBWIRE) -- 10/17/2019 -- The leading research firm Coherent Market Insights published a research report on "Cervical Cancer Drugs Market Size Analysis and Forecast 2026" which serves with all-inclusive, highly-effective, and thoroughly analyzed information in a well-organized manner, based on actual facts, about the Cervical Cancer Drugs Market. The whole information from scratch to the financial and management level of the established industries associated with the Cervical Cancer Drugs Market at the global level is initially acquired by the dedicated team. The gathered data involves the information about the industry's establishment, market Size, Share, type and the form of products it manufactures, annual sales and revenue generation, the demand of the manufactured product in the market, marketing trends followed by the industry, and a lot more important information.

Cervical cancer is a type of cancer that develops in women's cervix and mainly affects sexually active women aged between 30 and 45. Cervical cancer doesn't show any symptoms at the initial phase. Cervical cancer can be diagnosed by using a Pap test (Papanicolaou test), which is a screening test that can identify the changes taking place in the cervix before the development of cancer. The most common type of cervical cancer is squamous cell cancer and adenocarcinoma.

Request Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/1746

Market Drivers

The rising number of drug approval done by the U.S. Food and Drug Administration (FDA) for the treatment of cervical cancer is projected to drive the growth of the cervical cancer drug market over the forecast period. For instance, in September 2017, U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, which includes cervical, lung, brain, colorectal and kidney cancer. Mvasi is indicated for use in persistent, recurrent, or metastatic cervical cancer. In August 2014, the U.S. FDA approved Genentech's Avastin, which is bevacizumab solution for intravenous infusion in combination with paclitaxel for the treatment of persistent, recurrent, or metastatic cervical cancer.

Furthermore, rising funding for cancer research, improving insurance coverage, and growth in the number of new targeted cancer drugs are expected to support the revenue growth of the cervical cancer drugs market. For instance, National Cancer Institute, in 2015, spent around US$ 4,480 million on cancer research, which includes cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukemia, ovarian cancer, and uterine cancer. Furthermore, according to the American Cancer Society, the U.S. invested around US$ 87.8 billion in 2014 on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.

Rising incidence of cervical cancer among the global population, growth in incidence of HIV in women, lack of awareness regarding the diagnosis for prevention of invasive cancer is expected to drive the growth of the cervical cancer drugs market. Moreover, the American Cancer Society, in March 2018, funded around 22 grants for cervical cancer, which accounted for around US$ 9.3 million. The funding value is offered to a single or group of research, which includes a specific type of cancer or area of cancer. For instance, according to Cancer Research UK, 2015 data findings, around 3,200 new cervical cancer cases were registered in the UK annually from 2013 to 2015.

Moreover, according to the same source, in 2015, cervical cancer accounted for around 2% of all cancer cases in females in the UK. A joint study conducted on cervical cancer by the Associated Chambers of Commerce and Industry of India (ASSOCHAM) and National Institute of Cancer Prevention and Research (NICPR), published in January 2018, reported that India alone has one fourth of the global burden of cervical cancer, which accounts for 17% of all cancer deaths in women aged between 30 and 69 years in India. Moreover, according to the same source, it is estimated that around 1 in 53 Indian women are expected to be diagnosed with cervical cancer during their lifetime.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1746

Regional Analysis

Geographically, the cervical cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds a dominant position in the cervical cancer drugs market, and this can be attributed to increasing incidences of cervical cancer and growing research & development programs by various healthcare regulatory organizations in these region. For instance, according to the American Cancer Society's (ACS) estimates for cervical cancer in the U.S. for 2018, around 13, 240 new cases of invasive cervical cancer were diagnosed and around 4,170 women are expected to die from cervical cancer. For instance, in 2013, Cervical Cancer-Free Coalition (CCFC) announced a collaborative research projects with funds ranging from US$ 5,000-US $10,000 each, which are focused on cervical cancer treatment in the U.S.

Competitive Landscape

Some of the key players operating in the cervical cancer drugs market include F. Hoffmann-La Roche Ltd., Hetero, GlaxoSmithKline, plc, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., AstraZeneca plc, Allergan plc, Biocon Limited, Bristol-Myers Squibb Company, and Novartis AG. Key players operating in the market are focused on organic growth strategies, in order to enhance their market share and retain their competence in the market. For instance, in July 2014, MedImmune: a biologics research and development division of AstraZeneca entered into a clinical trial collaboration with Advaxis. According to the agreement, both companies conducted Phase I/II immunotherapy study to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor: MEDI4736, in combination with Advaxis' cancer immunotherapy vaccine: ADXS-HPV. This study is conducted to develop a treatment for patients with advanced, recurrent or refractory Human Papillomavirus (HPV)-associated cervical cancer.

Some Important TOC:

- Market Overview
- Global Cervical Cancer Drugs Market Landscape by Player
- Players Profiles
- Global Production, Revenue (Value), Price Trend by Type
- Market Analysis by Application
- Global Cervical Cancer Drugs Production, Consumption, Export, Import by Region (2013-2018)
- Production, Revenue (Value) by Region (2013-2018)
- Cervical Cancer Drugs Manufacturing Analysis
- Industrial Chain, Sourcing Strategy and Downstream Buyers
- Market Dynamics
- Global Cervical Cancer Drugs Market Forecast (2018-2026)
- Research Findings and Conclusion
- Appendix

To Get Instant Access, Purchase Report Here: https://www.coherentmarketinsights.com/insight/buy-now/1746

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.